Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative anti-HER2 therapy biological study in early HER2-positive breast cancer
ISRCTN15004993Phase 3Completed
- Sponsor
- The University of Manchester
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of trastuzumab and lapatinib in breast cancer (3 arms), sponsored by The University of Manchester. Primary endpoints: Increase in apoptosis and Fall in proliferation between diagnosis and surgery. Started Apr 2010; status: completed.
02
Drugs
trastuzumablapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN15004993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15004993.